Literature DB >> 29164407

Neurological Complications of HIV Infection.

Shelli Farhadian1, Payal Patel2, Serena Spudich3.   

Abstract

PURPOSE OF REVIEW: HIV-associated neurocognitive disorders (HAND) are common in patients with HIV disease, even during suppressive combination antiretroviral therapy (cART). This review article addresses the pathogenesis of HAND, focusing on important findings from the last 5 years. RECENT
FINDINGS: While HIV-associated dementia is now rare in settings with cART availability, mild forms of HAND are increasing in prevalence. Biomarkers of cellular injury, such as neurofilament light chain and neopterin, can detect early stages of neuroinflammation associated with HIV infection and are increased even in asymptomatic individuals with chronic HIV infection. Several recent studies form a growing body of evidence that HIV can infect and replicate in monocytes and that blocking monocyte activity can potentially improve neurological outcomes in HIV. Early cART may also prevent HAND. Understanding the multifactorial causes of CNS infection and inflammation is critical to devising treatment and preventive strategies for HAND.

Entities:  

Keywords:  CNS escape; HIV; HIV-associated neurocognitive disorder; Immune activation

Year:  2017        PMID: 29164407     DOI: 10.1007/s11908-017-0606-5

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  61 in total

Review 1.  The neuropathogenesis of AIDS.

Authors:  Francisco González-Scarano; Julio Martín-García
Journal:  Nat Rev Immunol       Date:  2005-01       Impact factor: 53.106

2.  Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa.

Authors:  N Sacktor; N Nakasujja; R Skolasky; K Robertson; M Wong; S Musisi; A Ronald; E Katabira
Journal:  Neurology       Date:  2006-07-25       Impact factor: 9.910

3.  Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline.

Authors:  Igor Grant; Donald R Franklin; Reena Deutsch; Steven P Woods; Florin Vaida; Ronald J Ellis; Scott L Letendre; Thomas D Marcotte; J H Atkinson; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Justin C McArthur; Susan Morgello; David M Simpson; John A McCutchan; Ian Abramson; Anthony Gamst; Christine Fennema-Notestine; Davey M Smith; Robert K Heaton
Journal:  Neurology       Date:  2014-05-09       Impact factor: 9.910

4.  Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.

Authors:  Peter Derek Christian Leutscher; Chalotte Stecher; Merete Storgaard; Carsten Schade Larsen
Journal:  Scand J Infect Dis       Date:  2013-02-21

5.  HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads.

Authors:  Susanna L Lamers; Rebecca Rose; Ekaterina Maidji; Melissa Agsalda-Garcia; David J Nolan; Gary B Fogel; Marco Salemi; Debra L Garcia; Paige Bracci; William Yong; Deborah Commins; Jonathan Said; Negar Khanlou; Charles H Hinkin; Miguel Valdes Sueiras; Glenn Mathisen; Suzanne Donovan; Bruce Shiramizu; Cheryl A Stoddart; Michael S McGrath; Elyse J Singer
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

6.  Cognitive functioning in younger and older HIV-1-infected adults.

Authors:  Frances L Wilkie; Karl Goodkin; Imad Khamis; Maria H van Zuilen; Diana Lee; Robert Lecusay; Mauricio Concha; Stephen Symes; Paola Suarez; Carl Eisdorfer
Journal:  J Acquir Immune Defic Syndr       Date:  2003-06-01       Impact factor: 3.731

7.  Neuropsychological Impairment in Acute HIV and the Effect of Immediate Antiretroviral Therapy.

Authors:  Idil Kore; Jintanat Ananworanich; Victor Valcour; James L K Fletcher; Thep Chalermchai; Robert Paul; Jesse Reynolds; Somporn Tipsuk; Sasiwimol Ubolyam; Somprartthana Rattanamanee; Linda Jagodzinski; Jerome Kim; Serena Spudich
Journal:  J Acquir Immune Defic Syndr       Date:  2015-12-01       Impact factor: 3.731

8.  Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.

Authors:  Serena S Spudich; Annelie C Nilsson; Nicole D Lollo; Teri J Liegler; Christos J Petropoulos; Steven G Deeks; Ellen E Paxinos; Richard W Price
Journal:  BMC Infect Dis       Date:  2005-11-02       Impact factor: 3.090

9.  HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy.

Authors:  Jenna B Honeycutt; William O Thayer; Caroline E Baker; Ruy M Ribeiro; Steven M Lada; Youfang Cao; Rachel A Cleary; Michael G Hudgens; Douglas D Richman; J Victor Garcia
Journal:  Nat Med       Date:  2017-04-17       Impact factor: 53.440

10.  Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid.

Authors:  Oliver M Grauer; Doris Reichelt; Ute Grüneberg; Hubertus Lohmann; Tilman Schneider-Hohendorf; Andreas Schulte-Mecklenbeck; Catharina C Gross; Sven G Meuth; Heinz Wiendl; Ingo W Husstedt
Journal:  Ann Clin Transl Neurol       Date:  2015-08-18       Impact factor: 4.511

View more
  28 in total

1.  Nitrosative Stress Is Associated with Dopaminergic Dysfunction in the HIV-1 Transgenic Rat.

Authors:  Swati Shah; Dragan Maric; Frank Denaro; Wael Ibrahim; Ronald Mason; Ashutosh Kumar; Dima A Hammoud; William Reid
Journal:  Am J Pathol       Date:  2019-07       Impact factor: 4.307

Review 2.  Brain PET Imaging: Value for Understanding the Pathophysiology of HIV-associated Neurocognitive Disorder (HAND).

Authors:  Sanhita Sinharay; Dima A Hammoud
Journal:  Curr HIV/AIDS Rep       Date:  2019-02       Impact factor: 5.071

Review 3.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

Review 4.  Current trends and new developments in HIV research and periodontal diseases.

Authors:  Mark I Ryder; Caroline Shiboski; Tzy-Jyun Yao; Anna-Barbara Moscicki
Journal:  Periodontol 2000       Date:  2020-02       Impact factor: 7.589

Review 5.  Role of T Lymphocytes in HIV Neuropathogenesis.

Authors:  Caroline Subra; Lydie Trautmann
Journal:  Curr HIV/AIDS Rep       Date:  2019-06       Impact factor: 5.071

6.  Ultradeep HIV-1 Proviral Envelope Sequencing Reveals Complex Population Structure within and between Brain and Splenic Tissues.

Authors:  Rebecca Rose; Maria Paz Gonzalez-Perez; David J Nolan; Sissy Cross; Susanna L Lamers; Katherine Luzuriaga
Journal:  J Virol       Date:  2021-09-08       Impact factor: 5.103

7.  HIV and FIV glycoproteins increase cellular tau pathology via cGMP-dependent kinase II activation.

Authors:  Matheus F Sathler; Michael J Doolittle; James A Cockrell; India R Nadalin; Franz Hofmann; Sue VandeWoude; Seonil Kim
Journal:  J Cell Sci       Date:  2022-06-21       Impact factor: 5.235

8.  Antiretroviral concentrations and surrogate measures of efficacy in the brain tissue and CSF of preclinical species.

Authors:  Nithya Srinivas; Elias P Rosen; William M Gilliland; Martina Kovarova; Leila Remling-Mulder; Gabriela De La Cruz; Nicole White; Lourdes Adamson; Amanda P Schauer; Craig Sykes; Paul Luciw; J Victor Garcia; Ramesh Akkina; Angela D M Kashuba
Journal:  Xenobiotica       Date:  2018-12-17       Impact factor: 1.908

9.  Treatment with buprenorphine prior to EcoHIV infection of mice prevents the development of neurocognitive impairment.

Authors:  Matias Jaureguiberry-Bravo; Jennifer Kelschenbach; Aniella Murphy; Loreto Carvallo; Eran Hadas; Lydia Tesfa; Travis M Scott; Monica Rivera-Mindt; Chinazo O Cunningham; Julia H Arnsten; David J Volsky; Joan W Berman
Journal:  J Leukoc Biol       Date:  2020-06-24       Impact factor: 4.962

10.  Comparison of dementia risk after age 50 between individuals with and without HIV infection.

Authors:  Jennifer O Lam; Craig E Hou; J Carlo Hojilla; Alexandra N Anderson; Paola Gilsanz; Stacey E Alexeeff; Tory Levine-Hall; Nicole Hood; Catherine Lee; Derek D Satre; Michael J Silverberg
Journal:  AIDS       Date:  2021-04-01       Impact factor: 4.632

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.